文献速递浆细胞疾病

苯达莫司汀联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤:一项II期试验

Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
PubMed 文献 · Br J Haematol · 2022-05-02

该II期研究评估苯达莫司汀、泊马度胺和地塞米松联合方案治疗复发/难治性多发性骨髓瘤,2020年2月至2021年12月纳入28例患者。中位随访8.6个月,总缓解率为57.6%,中位无进展生存期6.2个月,中位总生存期9.7个月;毒性以血液学为主,可控。

要点

  • 苯达莫司汀+泊马度胺+地塞米松方案在重度经治复发/难治性骨髓瘤中总缓解率达57.6%。
  • 中位随访8.6个月时,中位无进展生存期6.2个月,中位总生存期9.7个月。
  • 主要毒性为血液学毒性:中性粒细胞减少46.4%、贫血42.8%、血小板减少7.1%。

核心结论

  • 苯达莫司汀、泊马度胺和地塞米松联合方案可能成为重度经治、来那度胺难治性骨髓瘤患者的新选择。

研究设计与样本

  • II期研究,2020年2月至2021年12月共纳入28例复发/难治性多发性骨髓瘤患者。
  • 患者接受苯达莫司汀120 mg/m²第1天、泊马度胺3 mg第1-21天、地塞米松40 mg第1、8、11、22天,最多六个周期。
  • 主要终点为至少三个周期后≥部分缓解的总缓解率,次要终点为毒性、无进展生存期、至进展时间和总生存期,采用意向性治疗分析。

主要发现

  • 患者中位(范围)年龄54(30-76)岁,男性15例(53.6%)。
  • 患者既往接受中位(范围)三(二至六)线治疗,85.7%同时对来那度胺和硼替佐米难治。
  • 总缓解率为57.6%,髓外骨髓瘤患者缓解率更高。
  • 中位随访8.6个月时,中位无进展生存期6.2个月,中位总生存期9.7个月。
  • 毒性可控,主要为血液学毒性:中性粒细胞减少46.4%、贫血42.8%、血小板减少7.1%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of patients with resistant/refractory multiple myeloma (MM) is an unmet need. In this phase II study, we evaluated the role of bendamustine, pomalidomide and dexamethasone combination in this setting. Between February 2020 and December 2021, 28 patients were recruited. Patients received bendamustine 120 mg/m2 day 1, pomalidomide 3 mg days 1-21, and dexamethasone 40 mg days 1, 8, 11, 22, regimen given for a maximum of six cycles. The median (range) age of the patients was 54 (30-76) years and 15 (53.6%) were males. Patients had received a median (range) of three (two-six) prior lines and 85.7% were refractory to both lenalidomide and bortezomib. The primary end-point was the overall response rate (ORR) defined as ≥partial response after at least three cycles. Secondary objectives were toxicity, progression-free survival (PFS), time to progression and overall survival (OS). An intent-to-treat analysis was done. An ORR of 57.6% was achieved. Patients with extramedullary myeloma had a better response rate. At a median follow-up of 8.6 months, the median PFS and OS were 6.2 and 9.7 months respectively. Toxicity was manageable; mainly haematological (neutropenia, 46.4%; anaemia, 42.8%; and thrombocytopenia, 7.1%). Bendamustine, pomalidomide and dexamethasone could be a novel combination for the heavily pretreated, lenalidomide-refractory myeloma population.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kumar S, Sharma A, Malik PS, et al. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial. Br J Haematol. 2022. PMID: 35499209. doi:10.1111/bjh.18200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。